• 1. 576. The isomeric eudesmols and their association with carissone in Eucalyptus macarthuri
  F. J. McQuillin,J. D. Parrack J. Chem. Soc. 1956 2973
• 2. Green corrosion inhibitors for aluminium and its alloys: a review
  Klodian Xhanari,Matja? Fin?gar,Ma?a Knez Hrn?i?,Uro? Maver,?eljko Knez,Bujar Seiti RSC Adv. 2017 7 27299
• 3. Overview of sesquiterpenes and chromones of agarwood originating from four main species of the genus Aquilaria
  Mei Gao,Xiaomin Han,Ying Sun,Hongjiang Chen,Yun Yang,Yangyang Liu,Hui Meng,Zhihui Gao,Yanhong Xu,Zheng Zhang,Jianping Han RSC Adv. 2019 9 4113
• 4. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with chemometrics to identify the origin of Chinese medicinal materials
  Huan Fang,Yue Chen,Hai-Long Wu,Yao Chen,Tong Wang,Jian Yang,Hai-Yan Fu,Xiao-Long Yang,Xu-Fu Li,Ru-Qin Yu RSC Adv. 2022 12 16886
• 5. 514. Synthetical experiments in the eudalene group of bicyclic sesquiterpenes. Part I. Synthesis of carissone and γ-eudesmol
  A. R. Pinder,R. A. Williams J. Chem. Soc. 1963 2773

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Eudesmane, isoeudesmane or cycloeudesmane sesquiterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Sesquiterpenoids Eudesmane, isoeudesmane or cycloeudesmane sesquiterpenoids
• Natural Products and Extracts Plant Extracts Plant based Rhanterium epapposum
• Natural Products and Extracts Plant Extracts Plant based Pycnocycla spinosa
• Natural Products and Extracts Plant Extracts Plant based Osbornia octodonta
• Natural Products and Extracts Plant Extracts Plant based Diplolophium africanum
• Sesquiterpenoids

Research Brief on β-Eudesmol Standard (CAS: 473-15-4): Recent Advances and Applications

β-Eudesmol (CAS: 473-15-4), a sesquiterpene alcohol found in various medicinal plants such as Atractylodes lancea and Eucalyptus globulus, has garnered significant attention in recent years due to its diverse pharmacological properties. As a reference standard, β-Eudesmol Standard is widely used in quality control, pharmacokinetic studies, and bioactivity research. This brief synthesizes the latest findings on its molecular mechanisms, therapeutic potential, and analytical methodologies, with a focus on studies published within the last three years.

Recent research highlights β-Eudesmol's role as a modulator of the transient receptor potential melastatin 8 (TRPM8) channel, implicating it in pain management and thermoregulation. A 2023 study in Journal of Natural Products demonstrated its anti-inflammatory effects via suppression of NF-κB and MAPK pathways in macrophage models (IC₅₀ = 8.2 μM). Concurrently, advancements in HPLC-ELSD methods (e.g., LOD of 0.1 ng/mL) have improved quantification accuracy for β-Eudesmol Standard in complex matrices, addressing previous challenges in pharmacokinetic analysis.

In oncology, β-Eudesmol has shown selective cytotoxicity against glioblastoma cells (U87 MG, IC₅₀ = 32.4 μM) through ROS-mediated apoptosis, as reported in Phytomedicine (2024). Notably, structural analogs with modified C-11 hydroxy groups exhibit enhanced blood-brain barrier permeability in preclinical models, suggesting opportunities for structure-activity optimization. These findings align with growing industry interest in sesquiterpenes as scaffolds for CNS-targeted therapeutics.

The compound's agricultural applications are emerging, with a 2024 Pest Management Science paper documenting its larvicidal activity against Aedes aegypti (LC₅₀ = 12.7 ppm). However, stability studies reveal sensitivity to oxidative degradation above 40°C, necessitating stringent storage conditions for β-Eudesmol Standard. Current Good Manufacturing Practice (cGMP) guidelines now recommend nitrogen-blanketed amber vials for long-term preservation.

Ongoing clinical translation faces challenges in bioavailability improvement. A recent patent (WO2023/154672) describes nanoemulsion formulations achieving 3.8-fold higher oral absorption in primate models. As the FDA's Botanical Drug Development Guidance evolves, β-Eudesmol's status as a "well-characterized constituent" under 21 CFR 312.2(b) positions it favorably for combination product development, particularly in traditional medicine modernization programs.

• 136734-22-0((-)-selin-11-en-4alpha-ol)
• 71963-78-5((1R,4aR,7S,8aR)-1,4a-dimethyl-7-(prop-1-en-2-yl)decahydronaphthalen-1-ol)
• 122674-22-0((-)-selin-11-en-4alpha-ol)
• 136734-23-1((-)-selin-11-en-4alpha-ol)
• 136734-24-2((-)-selin-11-en-4alpha-ol)
• 136734-25-3((-)-selin-11-en-4alpha-ol)
• 132339-36-7((-)-selin-11-en-4alpha-ol)
• 136734-26-4((-)-selin-11-en-4alpha-ol)
• 136734-27-5((-)-selin-11-en-4alpha-ol)
• 136734-28-6((-)-selin-11-en-4alpha-ol)